Glycopeptide Utilizing Patents (Class 514/20.9)
  • Patent number: 10383796
    Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: August 20, 2019
    Assignee: Lubris LLC
    Inventors: Edward R. Truitt, Nicole Barbara Justis Truitt
  • Patent number: 10300169
    Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 28, 2019
    Assignee: Allergan, Inc.
    Inventors: Xiaojie Yu, Darin J. Messina, Elizabeta Pavlovic, Cunqi Cui, Kate M. Smither
  • Patent number: 10287317
    Abstract: This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 14, 2019
    Assignee: SRX Cardio, LLC
    Inventors: Michael M. Muehlemann, Thomas E. Barta, Kyle D. Monroe, Jonathan William Bourne, Margaret Thompson Reece, Vesa Nevalainen, Eric T. Baldwin
  • Patent number: 10188707
    Abstract: The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: January 29, 2019
    Assignee: Berg, LLC
    Inventors: Niven Rajin Narain, Rangaprasad Sarangarajan, Vivek K. Vishnudas, Stephane Gesta, Enxuan Jing
  • Patent number: 10172917
    Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of Zn-?2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as ? adrenergin receptor agonists, ? adrenergin receptor antagonists, and/or glycemic control agents.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 8, 2019
    Assignee: Aston University
    Inventors: Michael Tisdale, Steven Russell
  • Patent number: 10106829
    Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: October 23, 2018
    Assignee: Amgen Inc.
    Inventors: Shivani Gupta, Sohye Kang
  • Patent number: 10053499
    Abstract: The object of the present invention is to provide a polypeptide having interferon ? activity glycosylated with highly uniform sialylated sugar chains. The present invention is a glycosylated polypeptide, wherein the polypeptide is any polypeptide selected from the group consisting of the following (1) to (4); (1) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, (2) a polypeptide having one or a few amino acids deleted, substituted, or added in the polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, (3) a polypeptide that is an analog of interferon ?, and (4) a polypeptide having 80% or more homology to the polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, in which amino acids at 4 to 6 locations are substituted with glycosylated amino acids, and wherein all of the non-reducing terminals of said sugar chain are sialylated.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: August 21, 2018
    Assignee: GLYTECH, INC.
    Inventors: Masaki Ohuchi, Mika Nishihara, Katsunari Tezuka, Masatoshi Maeda, Yasuhiro Kajihara, Izumi Sakamoto
  • Patent number: 9988661
    Abstract: The present invention relates to a process for the enzymatic modification of a glycoprotein. The process comprises the step of contacting a glycoprotein comprising a glycan comprising a terminal GlcNAc-moiety, in the presence of glycosyltransferase that is, or is derived from, a ?-(1,4)-N-acetylgalactosaminyltransferase, with a non-natural sugar-derivative nucleotide. The non-natural sugar-derivative nucleotide is according to formula (3): wherein A is selected from the group consisting of —N3, —C(O)R3, —(CH2)iC?C—R4, —SH, —SC(O)R8, —SC(O)OR8, —SC(S)OR8, —F, —CI, —Br —I, —OS(O)2R5, terminal C2-C24 alkenyl groups, C3-C5 cycloalkenyl groups, C4-C8 alkadienyl groups, terminal C3-C24 allenyl groups and amino groups.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: June 5, 2018
    Assignee: SynAffix B.V.
    Inventors: Sander Sebastiaan Van Berkel, Remon Van Geel, Maria Antonia Wijdeven, Floris Louis Van Delft
  • Patent number: 9840710
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 12, 2017
    Assignees: Rosalind Franklin University of Medicine and Science, The McLean Hospital Corporation
    Inventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
  • Patent number: 9815876
    Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: November 14, 2017
    Assignee: Omeros Corporation
    Inventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
  • Patent number: 9732132
    Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: August 15, 2017
    Assignee: Vanderbilt University
    Inventors: Tonia S. Rex, Timothy A. Sullivan
  • Patent number: 9598474
    Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 21, 2017
    Assignee: Axcella Health, Inc.
    Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Rajeev Chillakuru, Michael Hamill, John F. Kramarczyk
  • Patent number: 9512172
    Abstract: Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 6, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Patent number: 9447395
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: September 20, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9376669
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 28, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9322012
    Abstract: The present technology provides for enzyme compositions with enhanced enzyme activity, thermophilic and psychrophilic stability.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: April 26, 2016
    Assignee: UNIVERSITY OF CALCUTTA
    Inventors: Anjan Kr. Dasgupta, Tamoghna Bhattacharyya, Arka Mukhopadhyay, Nalok Dutta, Krishanu Chakraborty
  • Patent number: 9192668
    Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 24, 2015
    Assignee: PENTRAXIN THERAPEUTICS LIMITED
    Inventor: Mark B. Pepys
  • Patent number: 9175055
    Abstract: The invention relates to the use of fibromodulin and lumican, particularly active fragments thereof, to increase muscle mass, especially in the treatment of muscular dystrophies.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: November 3, 2015
    Assignee: ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventors: Antoine Kichler, Daniel Scherman
  • Publication number: 20150148301
    Abstract: The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 28, 2015
    Inventors: Virginie Clement-Schatlo, Thomas Fessard, Damien Barbaras, Joana Matos, Erick Carreira
  • Publication number: 20150140010
    Abstract: The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine protein kinase (CASK) in a blood sample obtained from the subject. The present invention also relates to an agent effective to inhibit the binding of CASK to hCD98 present on the surface of podocytes for use in the prevention or treatment of focal segmental glomerulosclerosis (FSGS) in a subject in need thereof.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Applicants: INSERM 9INSTITUT NATIONAL DE LA SANTE ET DE LA R- ECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Antoine Durrbach, Hanz Lorenzo, Severine Beaudreuil
  • Publication number: 20150139904
    Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 21, 2015
    Applicant: University of Miami
    Inventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Liu Zhao-Jun, Sapna Deo
  • Publication number: 20150140071
    Abstract: The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 21, 2015
    Inventor: Ayyappan K. Rajasekaran
  • Publication number: 20150133362
    Abstract: Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 14, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20150132279
    Abstract: A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 14, 2015
    Applicants: TEIJIN LIMITED, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, TEIJIN PHARMA LIMITED
    Inventors: Yukako Kageyama, Kentaro Fujinaga, Ayuko Yamaguchi, Yusuke Akiyama, Souichirou Katou, Yukiko Kimura, Susumu Honda, Makoto Satake, Hiroaki Kaneko, Ayumi Ishiwari, Masaki Hirashima
  • Patent number: 9029331
    Abstract: The invention relates to methods of preparing and purifying conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are purified using various chromatography methods.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Henrik Clausen, David A. Zopf, Caryn Bowe, Susann Taudte, Michael Felo, Walter S. Willett
  • Publication number: 20150125497
    Abstract: Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor.
    Type: Application
    Filed: December 10, 2014
    Publication date: May 7, 2015
    Inventor: Xiaoyang Qi
  • Publication number: 20150125531
    Abstract: Methods and compositions are provided that load and encapsulate an agent, such as a protein, in a porous self-healing polymer. A delivery system includes a porous self-healing polymer, an ionic affinity trap within the pores of the self-healing polymer, and an agent associated with the ionic affinity trap. Methods of encapsulating an agent in a polymer include providing a porous self-healing polymer comprising an ionic affinity trap within the pores. The polymer is incubated with an agent having an affinity for the ionic affinity trap. At least a portion of the pores in the polymer are then healed. Active encapsulation of macromolecules at low concentrations may be achieved due to affinity of the agent for the ionic affinity trap within the pores.
    Type: Application
    Filed: January 6, 2015
    Publication date: May 7, 2015
    Inventors: Steven P. Schwendeman, Kashappa-Goud Desai
  • Publication number: 20150118178
    Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 30, 2015
    Inventors: Cory Berkland, Joshua Sestak
  • Publication number: 20150111834
    Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.
    Type: Application
    Filed: September 17, 2014
    Publication date: April 23, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
  • Publication number: 20150099698
    Abstract: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.
    Type: Application
    Filed: October 8, 2013
    Publication date: April 9, 2015
    Inventors: Phillip Williams, Thomas Rademacher, Alexander Mark Schobel, Eric Dadey
  • Publication number: 20150087601
    Abstract: It is an object of the present invention to provide: a polyion complex that sufficiently retains a photosensitizing substance in serum and is excellent in terms of structural stability; a nucleic acid polyplex as a constituent thereof; and a device and a kit for delivering a nucleic acid into a cell. The nucleic acid polyplex of the present invention comprises a cationic polymer represented by general formula (1) and a nucleic acid. The polyion complex of the present invention comprises the nucleic acid polyplex of the present invention and an anionic photosensitizing substance.
    Type: Application
    Filed: November 3, 2014
    Publication date: March 26, 2015
    Inventors: Kazunori KATAOKA, Yuichi YAMASAKI, Nobuhiro NISHIYAMA, Woo-Dong JANG, Anwar ARNIDA
  • Publication number: 20150079055
    Abstract: An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
    Type: Application
    Filed: September 23, 2014
    Publication date: March 19, 2015
    Applicants: Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Publication number: 20150080318
    Abstract: A compound of the general formula (III): wherein X is O, S, NH or CH2; Y is O, S or NH; Z is O, S or CH2; R1 is C1-8 alkyl, especially C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl; at least one of R2 and R3 is H—[R4-R5]n—R6—, in which: H—[R4-R5]n— comprises an oligopeptide, R4 being an amino acid and R5 being an amino acid selected from proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine, R6 is a neutral, non-polar amino acid moiety that is bonded to R5 by a peptide bond, and n is 1, 2, 3, 4 or 5; and the other of R3 and R2 is H—[R4-R5]n—R6— or H; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventors: Jan Balzarini, Maria Jose Camarasa, Sonsoles Velazquez
  • Publication number: 20150080940
    Abstract: Described are embolization devices which carry M1 macrophage promoting agents and/or M2 macrophage inhibiting agents, as well as methods for their manufacture and use. An illustrative embolization device of the disclosure comprises an embolic body and one or more M1 macrophage promoting agents and/or M2 macrophage inhibiting agents carried by a surface of the embolic body. In certain embodiments the embolic body of the present disclosure comprises an embolic coil or an embolic bead.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 19, 2015
    Inventor: Colleen Gemborys
  • Patent number: 8980840
    Abstract: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 17, 2015
    Assignees: Schepens Eye Research Institute, Lubris LLC
    Inventors: Edward R. Truitt, III, Benjamin Sullivan, David Sullivan
  • Patent number: 8968722
    Abstract: The present disclosure relates to milk-based nutritional compositions comprising lactoferrin and/or a prebiotic component, wherein, when combined, the lactoferrin and prebiotic component may exhibit additive or synergistic beneficial effects on the health and development of a pediatric subject. The disclosure further relates to methods comprising the administration of said milk-based nutritional compositions to pediatric subjects.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: March 3, 2015
    Assignee: Mead Johnson Nutrition Company
    Inventor: Anja Wittke
  • Patent number: 8956604
    Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: February 17, 2015
    Assignee: The University of Kansas
    Inventors: Cory Berkland, Joshua Sestak
  • Publication number: 20150031619
    Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.
    Type: Application
    Filed: August 22, 2014
    Publication date: January 29, 2015
    Inventors: Alyssa Panitch, John E. Paderi, Kinam Park, Katherine Stuart, Steve Higbee
  • Publication number: 20150030595
    Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 29, 2015
    Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
  • Publication number: 20150031630
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: May 17, 2012
    Publication date: January 29, 2015
    Inventor: John J. Nestor
  • Publication number: 20150018267
    Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory Agent
    Type: Application
    Filed: August 6, 2012
    Publication date: January 15, 2015
    Applicant: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
    Inventors: Patricia A. D'Amore, Pablo Argüeso, Alisar S. Zahr
  • Publication number: 20150017235
    Abstract: New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 15, 2015
    Inventors: Massimo MASSERINI, Francesca RE, Giulio SANCINI, Gianluigi FORLONI, Mario SALMONA
  • Publication number: 20150010643
    Abstract: This invention relates to a method of treating B cell malignancies, which involves administering to a subject a compound having a structure of formula (I) to cause cell death of a B cell malignancy, thereby treating the B cell malignancy in the subject. Also disclosed are a method of causing cell death of malignant B cells, pharmaceutical compositions and therapeutic systems comprising a compound having a structure of formula (I), and a compound having a structure of formula (I).
    Type: Application
    Filed: February 15, 2013
    Publication date: January 8, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventor: Jiyong Zhao
  • Publication number: 20150005240
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 1, 2015
    Applicant: Instituto Massone S.A.
    Inventors: Miguel Angel Castellano, José F. Groisman, Liliana Ester Balanian, Felipe Inserra, Emilio Sojo, Claudio Fernando Wolfenson Band
  • Publication number: 20140379094
    Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.
    Type: Application
    Filed: May 16, 2014
    Publication date: December 25, 2014
    Applicants: TRUSTEES OF TUFTS COLLEGE, UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE AFM, UNIVERSITY OF ILLINOIS AT CHICAGO
    Inventors: David L. Kaplan, Jia Huang, Cheryl Wong Po Foo, Rajesh Naik, Anne George
  • Publication number: 20140371137
    Abstract: The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make them useful for inhibiting translation of target mRNA in vivo.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 18, 2014
    Inventors: Virendra Pandey, Jean-Luc Decout, Indrajit Das, Jerome Desire
  • Publication number: 20140369971
    Abstract: The present invention provides a fibromodulin (FMOD) reprogrammed (FReP) cell and a method of making therefor, a culture medium therefor, and a supernatant thereof, and methods of making and using these.
    Type: Application
    Filed: October 22, 2012
    Publication date: December 18, 2014
    Inventors: B. Chia Soo, Kang Ting, Zhong Zheng
  • Publication number: 20140369964
    Abstract: The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon ? activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon ? activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments.
    Type: Application
    Filed: September 28, 2012
    Publication date: December 18, 2014
    Inventors: Izumi Sakamoto, Kazuhiro Fukae, Katsunari Tezuka, Keisuke Tazuru, Masatoshi Maeda, Yasuhiro Kajihara, Takashi Tsuji
  • Publication number: 20140364373
    Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers' diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-Clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-Clostridial agent selected from the above combined with an opioid blocking agent.
    Type: Application
    Filed: July 7, 2014
    Publication date: December 11, 2014
    Inventor: Thomas Julius BORODY
  • Patent number: 8906380
    Abstract: Methods are disclosed which are useful in increasing maturation of dendritic cells from CD14+ mononuclear cells, by contact with a composition comprising a fucose-containing glycoprotein fraction from Ganoderma lucidum. The extract can also be used for increasing production of a cytokine or a chemokine in a dendritic cell or CD19+ B cell. In addition, a fucose-containing glycoprotein fraction from Ganoderma lucidum can be administered to a subject identified as needing increased immunoglobulin, cytokine, or chemokine production.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: December 9, 2014
    Assignee: Academia Sinica
    Inventors: Alice Yu, John Yu, Kuo-I Lin, Wen-Bin Yang, Chi-Huey Wong